| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2014-01-21 |
| タイトル |
|
|
タイトル |
Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations |
| 言語 |
|
|
言語 |
eng |
| DOI |
|
|
|
関連識別子 |
https://doi.org/10.3892/ol.2012.779 |
|
|
関連名称 |
10.3892/ol.2012.779 |
| キーワード |
|
|
主題 |
sunitinib, SU12662 (N-desethyl sunitinib), gastrointestinal stromal tumor, thrombocytopenia |
| 資源タイプ |
|
|
資源 |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
| 著者 |
Hashita, Tadahiro
Katsuyama, Yoshihiko
Nakamura, Katsunori
Momose, Yasuyuki
Komatsu, Daisuke
Koide, Naohiko
Miyagawa, Shinichi
Nakamura, Tomonori
Yamamoto, Koujirou
Ohmori, Shigeru
|
| 出版者 |
|
|
出版者 |
SPANDIDOS PUBL LTD |
| 引用 |
|
|
内容記述 |
ONCOLOGY LETTERS. 4(3):501-504 (2012) |
| 書誌情報 |
ONCOLOGY LETTERS
巻 4,
号 3,
p. 501-504,
発行日 2012-09
|
| 抄録 |
|
|
内容記述 |
In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal tumor (GIST). A 60-year-old woman with small intestinal GIST developed severe thrombocytopenia (1.7x10(4)/mu l) following 1 week of treatment with sunitinib at 50 mg/day. Although the dose of sunitinib was reduced to 25 mg/day, platelet levels remained low. On day 7, the trough concentration of sunitinib plus SU12662 was 4-6.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng.h/l. The dose was again reduced to 12.5 mg/day. However, the day after resumption of treatment, the patient developed symptoms of left heart failure due to myocardosis caused by sunitinib. Sunitinib has been reported to inhibit platelet-derived growth factor receptor (PDGFR) phosphorylation at concentrations over the range of 50-100 ng/ml (sunitinib plus SU12662) in vivo. In this case, the plasma concentration was sufficient to inhibit PDGFR at 25 or 50 mg/day. However, thrombocytopenia appeared at both dosages. Although the results in this case did not suggest a correlation between thrombocytopenia and plasma concentration, the degree of thrombocytopenia was decreased by reduction of the dose. In conclusion, the findings reported here indicate that the plasma concentration of sunitinib plus SU12662 is an important indicator to reduce adverse effects. |
| 資源タイプ（コンテンツの種類） |
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1792-1074 |
| PubMed |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
https://pubmed.ncbi.nlm.nih.gov/22970046 |
|
|
関連名称 |
22970046 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| WoS |
|
|
URL |
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000307201800025 |
Treatment_GIST_patient_with_modified_dose.pdf (307.8 kB)
